Virios Therapeutics (VIRI) Competitors $1.87 -0.06 (-3.11%) As of 01/17/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends VIRI vs. IKT, CYBN, CGEN, CRDF, ACRS, SLN, SCPH, ALEC, LYEL, and GNFTShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Inhibikase Therapeutics (IKT), Cybin (CYBN), Compugen (CGEN), Cardiff Oncology (CRDF), Aclaris Therapeutics (ACRS), Silence Therapeutics (SLN), scPharmaceuticals (SCPH), Alector (ALEC), Lyell Immunopharma (LYEL), and Genfit (GNFT). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Inhibikase Therapeutics Cybin Compugen Cardiff Oncology Aclaris Therapeutics Silence Therapeutics scPharmaceuticals Alector Lyell Immunopharma Genfit Inhibikase Therapeutics (NYSE:IKT) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends. Do analysts prefer IKT or VIRI? Inhibikase Therapeutics currently has a consensus price target of $6.50, indicating a potential upside of 138.97%. Virios Therapeutics has a consensus price target of $3.00, indicating a potential upside of 60.43%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Inhibikase Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer IKT or VIRI? In the previous week, Inhibikase Therapeutics' average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score. Company Overall Sentiment Inhibikase Therapeutics Neutral Virios Therapeutics Neutral Which has stronger earnings and valuation, IKT or VIRI? Virios Therapeutics has lower revenue, but higher earnings than Inhibikase Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase Therapeutics$260K725.61-$19.03M-$2.67-1.02Virios TherapeuticsN/AN/A-$5.30M-$0.27-6.93 Is IKT or VIRI more profitable? Virios Therapeutics' return on equity of -130.33% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% Virios Therapeutics N/A -130.33%-115.00% Do institutionals and insiders believe in IKT or VIRI? 3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 4.6% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, IKT or VIRI? Inhibikase Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Does the MarketBeat Community prefer IKT or VIRI? Inhibikase Therapeutics received 6 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 90.00% of users gave Inhibikase Therapeutics an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformInhibikase TherapeuticsOutperform Votes990.00% Underperform Votes110.00%Virios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% SummaryVirios Therapeutics beats Inhibikase Therapeutics on 7 of the 13 factors compared between the two stocks. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.01M$6.50B$5.34B$9.12BDividend YieldN/A2.95%5.37%4.01%P/E Ratio-6.934.3657.4613.13Price / SalesN/A310.771,272.2275.82Price / CashN/A22.8736.6632.72Price / Book9.354.964.884.58Net Income-$5.30M$154.90M$118.05M$224.83M7 Day Performance-19.40%1.35%1.45%2.37%1 Month Performance-19.40%0.41%2.50%4.40%1 Year Performance130.58%3.08%25.79%20.10% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$1.87-3.1%$3.00+60.4%+130.6%$36.01MN/A-6.935Gap UpIKTInhibikase Therapeutics1.6595 of 5 stars$2.66-9.8%$6.50+144.4%+58.2%$178.73M$260,000.00-1.006CYBNCybin2.9333 of 5 stars$8.90+0.1%$138.00+1,450.6%N/A$177.93MN/A-1.3450Positive NewsCGENCompugen2.2713 of 5 stars$1.99+21.3%$4.00+101.0%+16.0%$177.58M$59.85M99.5070High Trading VolumeCRDFCardiff Oncology2.1478 of 5 stars$3.47-3.9%$10.33+197.8%+128.5%$177.44M$688,000.00-3.6920Positive NewsACRSAclaris Therapeutics4.0912 of 5 stars$2.48+0.4%$11.00+343.5%+125.4%$177.15M$27.08M-4.7786Short Interest ↑High Trading VolumeSLNSilence Therapeutics2.1074 of 5 stars$5.90-1.5%$57.20+869.5%-72.2%$176.58M$16.25M-3.76100SCPHscPharmaceuticals3.3354 of 5 stars$3.51+3.2%$15.00+327.4%-38.6%$175.64M$30.28M-1.8530ALECAlector4.5046 of 5 stars$1.79-0.6%$3.75+109.5%-70.9%$175.30M$61.51M-1.05270Short Interest ↓Positive NewsLYELLyell Immunopharma2.2103 of 5 stars$0.59-1.7%$1.00+68.4%-69.7%$173.46M$63,000.00-0.75270GNFTGenfit1.6411 of 5 stars$3.44-4.4%$13.00+277.9%+4.9%$171.99M$76.06M0.00120Short Interest ↑ Related Companies and Tools Related Companies Inhibikase Therapeutics Alternatives Cybin Alternatives Compugen Alternatives Cardiff Oncology Alternatives Aclaris Therapeutics Alternatives Silence Therapeutics Alternatives scPharmaceuticals Alternatives Alector Alternatives Lyell Immunopharma Alternatives Genfit Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VIRI) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
